November is Pancreatic Cancer Awareness Month GCAR in collaboration with pancreatic cancer experts and @PanCAN is developing IMPACT PDAC - Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancreatic Ductal Adenocarcinoma - a clinical trial that will accelerate

Partner with us to develop your therapy for pancreatic ductal adenocarcinoma in IMPACT PDAC. IMPACT PDAC is - powered by GCAR’s track record of innovating, operationalizing, and implementing the modernization of new #clinicaltrial designs. - supported by @PanCAN's patient

🇺🇸 Honoring Veterans Day 🇺🇸 Today we honor and thank all who have served. At GCAR, we’re proud to support the Military and Veterans PTSD Adaptive Platform Clinical Trial (M-PACT) - a groundbreaking effort to advance care for those affected by PTSD. Veterans are more likely than

We’re looking forward to providing an update on #GBMAGILE at #SNO2025! Join us on Saturday, Nov 22, for the poster session – come check out our poster TIP-10: ‘Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and

Going to #SNO? Connect with us to learn more about opportunities to evaluate your therapy in #GBMAGILE – an efficient, patient-centric, accelerated drug development solution that maximizes learning. With some of the world’s foremost clinical, translational, and basic science

This past weekend, GCAR staff, family, and friends participated in @theABTA's Los Angeles #BT5K to support the #braintumor community and raise funds for essential research and patient support services. 🧠🔬🩶 Among those present were GCAR’s Board Chair, Faramarz Yousefzadeh

Clinical trial eligibility often depends on factors like #braintumor type, overall health, and results from biomarker testing. Join our #MyTumorID webinar on Oct. 24 to learn more about how clinical trials work. 🔗 Save your spot today: https://t.co/xnnHGEa7vL

Grateful for a productive and inspiring few days together -  building connections, sharing ideas, and driving forward the work that unites us. Our annual retreat was a valuable opportunity to reflect on our progress, strengthen collaboration, and plan for what’s ahead. At GCAR,

This past weekend GCAR’s Director of Clinical Science, Dr. Heather Kling, presented an update on the forthcoming clinical trial IMPACT PDAC, Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancreatic Ductal Adenocarcinoma at the @PanCAN Scientific Summit in

We have the platform and urgency to transform ovarian cancer care, shares Dr. @AnilSoodMD , respected expert in gynecologic oncology. What we need now is you - industry innovators ready to evaluate new therapies. Let’s accelerate discovery together and bring hope to women facing

By partnering with us on our ovarian cancer platform trials, you can focus on what matters most - advancing your therapy to patients who urgently need it. Partner with us, visit: https://t.co/g6Yq5vcaOB #OvarianCancer #ClinicalTrial #MasterProtocol #OvarianCancerAwarenessMonth

Thank you to Dr. @AshleeLoughan, Clinical Neuropsychologist, Associate Professor of Neurosurgery at Virginia Commonwealth University, and Director of the @LiveNOWLab, for presenting to our team on the importance of patient-reported outcomes in clinical research. At GCAR, we

We’ve created a trial designed for speed, flexibility, and smarter decisions from proof-of-concept to registration. Dr. David Gershenson (@RareOvarCancers), respected expert in low grade serous ovarian cancer and member of the LGSOC master protocol leadership council, shares how

We are thrilled to share that GCAR is working hard to bring tinostamustine into GBM AGILE, a global adaptive platform trial designed to accelerate the identification of effective treatments for #glioblastoma (GBM). We plan to evaluate tinostamustine for newly diagnosed and

With a 5-year survival rate of just 50% in women with ovarian cancer, we need new treatments now. Leading gyn-onc, Dr. @beth_karlan shares this sense of urgency and has been at the forefront of the fight for innovation drug development. Dr. Karlan along with other leading

Too few treatments exist for #LGSOC shares Dr. Rachel Grisham, a member of the Low Grade Serous Ovarian Cancer Master Protocol leadership team. Together, we can change that. Join us in advancing new options for patients. Partner with us, visit: https://t.co/g6Yq5vcaOB

Ovarian cancer is the fifth leading cause of cancer-related deaths in women. There is an urgent need for more effective treatment options. Partner with us to accelerate development and bring new therapies to patients faster. #OvarianCancerAwarenessMonth

September is #OvarianCancerAwarenessMonth GCAR is dedicated to accelerating the advancement of new treatments for individuals with rare and life-threatening conditions including #ovariancancer. Our focus is on establishing platform trials that enhance efficiency, shorten drug

Seeking a #clinicaltrial? 🔎💊🧬 There are various resources available to help you identify suitable clinical research studies. Websites like https://t.co/oC379U1Avs provide a comprehensive database of ongoing trials. You can also consult with your doctor, local research

Master protocol designs provide clear advantages – speed, efficiency, and flexibility – yet they also involve additional considerations. 🧪⚖️ Curious about the opportunities? Check out our infographic to learn how these innovative trial designs are reshaping clinical research.